Bio-Rad Laboratories, Inc. reported its financial results for the second quarter and first half of 2026, revealing a net sales figure of $651.0 million for the three months ending June 30, 2026, a slight decrease from $651.6 million in the same period last year. For the first half of 2026, total net sales reached $1.243 billion, reflecting a marginal increase of 0.5% compared to $1.237 billion in the first half of 2025. The company experienced a net income of $371.4 million for the second quarter, up from $317.8 million in the prior year, while the first half of 2026 showed a net loss of $155.7 million, contrasting with a profit of $381.8 million in the same period of 2025.
The company noted several operational changes, including a restructuring plan initiated on July 31, 2026, aimed at improving performance and competitiveness. This plan is expected to incur pre-tax charges of approximately $80 to $90 million, primarily related to employee termination benefits and facility closures. Additionally, Bio-Rad completed the acquisition of Stilla Technologies in June 2025, with the final purchase price allocation resulting in a minor adjustment to goodwill.
In terms of operational metrics, Bio-Rad's Life Science segment reported sales of $252.0 million for the second quarter, a decrease of 4.1% year-over-year, while the Clinical Diagnostics segment saw an increase of 2.6% to $399.0 million. The company’s gross profit margin remained stable at 53.1% for the second quarter of 2026, compared to 53.0% in the same quarter of 2025. Selling, general, and administrative expenses rose to $212.0 million, attributed to higher employee-related costs.
Looking ahead, Bio-Rad anticipates continued challenges due to global economic conditions, including inflation and geopolitical tensions, particularly in the EMEA region. The company expects these factors to impact demand and logistics, particularly within its Clinical Diagnostics segment. Despite these challenges, Bio-Rad maintains a strong liquidity position, with $1.62 billion in cash, cash equivalents, and short-term investments as of June 30, 2026, which it believes will support its operational and strategic objectives in the coming year.
About BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products globally. Its Life Science segment offers instruments, reagents, and consumables for biological material analysis, serving research institutions, biopharma, and food safety markets. The Clinical Diagnostics segment provides integrated test systems and reagents for clinical laboratories worldwide. Bio-Rad’s business model emphasizes innovation, direct sales, and recurring revenue from consumables tied to installed diagnostic systems.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov